These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 622061

  • 1. [Aldosterone antagonists in coronary insufficiency].
    Osswald H.
    Med Klin; 1978 Jan 20; 73(3):84-8. PubMed ID: 622061
    [No Abstract] [Full Text] [Related]

  • 2. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S, Buch J.
    Eur J Cardiol; 1979 Aug 20; 10(2):143-9. PubMed ID: 477703
    [Abstract] [Full Text] [Related]

  • 3. [Study of the inotropic effect of potassium canrenoate by determining systolic time intervals].
    Vitolo E, Gambini E, Larovere MT, Rusconi F, Vitali GM.
    Boll Soc Ital Cardiol; 1979 Aug 20; 24(7):775-7. PubMed ID: 554665
    [No Abstract] [Full Text] [Related]

  • 4. [Indication and experience with an intravenously administered aldosterone-antagonist (soldactone) (author's transl)].
    Kirsch R.
    Schweiz Rundsch Med Prax; 1975 Nov 04; 64(44):1414-7. PubMed ID: 1236699
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The role of potassium-canrenoate on 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I, Sebeszta M, Harsányi A, Szabó G, Antalóczy Z.
    Acta Physiol Acad Sci Hung; 1978 Nov 04; 51(4):393-9. PubMed ID: 754480
    [Abstract] [Full Text] [Related]

  • 7. [Study of the inotropic effect of potassium-canrenoate by systolic time intervals technique (author's transl)].
    Vitolo E, Larovere MT, Gambini E, Rusconi F, Vitali GM.
    G Ital Cardiol; 1980 Nov 04; 10(10):1360-5. PubMed ID: 7239083
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC, Bräuninger HJ.
    MMW Munch Med Wochenschr; 1975 Sep 04; 117(37):1483-6. PubMed ID: 810673
    [Abstract] [Full Text] [Related]

  • 10. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S, Bellati G, Ideo G.
    Minerva Dietol Gastroenterol; 1984 Sep 04; 30(3):255-61. PubMed ID: 6504374
    [No Abstract] [Full Text] [Related]

  • 11. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M, Cuppone R, Ricci GL.
    Arzneimittelforschung; 1988 Oct 04; 38(10):1492-5. PubMed ID: 3058132
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical study of potassium canrenoate on raised intracranial pressure.
    Node Y, Nakazawa S.
    Adv Neurol; 1990 Oct 04; 52():557. PubMed ID: 2396562
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [New aspects of treatment of hemodynamic complications in acute myocardial infarction (author's transl)].
    Schröder R.
    Arzneimittelforschung; 1977 Oct 04; 27(3a):722-8. PubMed ID: 405976
    [Abstract] [Full Text] [Related]

  • 19. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M, Vizzini GB.
    Minerva Med; 1986 Jan 28; 77(3-4):87-91. PubMed ID: 3511409
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.